Literature DB >> 11258197

ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2.

R Kerb1, S Hoffmeyer, U Brinkmann.   

Abstract

Transport by ATP-dependent efflux pumps, such as P-glycoprotein (PGP) and multi-drug resistance related proteins (MRPs), influences bioavailability and disposition of drugs. These efflux pumps serve as defence mechanisms and determine bioavailability and CNS concentrations of many drugs. However, despite the fact that substantial data have been accumulated on the structure, function and pharmacological role of ABC transporters and even though modification of PGP function is an important mechanism of drug interactions and adverse effects in humans, there is a striking lack of data on variability of the underlying genes. This review focuses on the human drug transporter proteins PGP (MDR1) and the multi-drug resistance proteins MRP1 and MRP2. An overview is provided of pharmacologically relevant genetic, structural and functional data as well as on hereditary polymorphisms, their phenotypical consequences and pharmacological implications.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11258197     DOI: 10.1517/14622416.2.1.51

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  34 in total

1.  Establishment and identification of the human multi-drug-resistant cholangiocarcinoma cell line QBC939/ADM.

Authors:  Zhi-Hua Liu; Yan-Ping He; Yukun Zhou; Peng Zhang; Huanlong Qin
Journal:  Mol Biol Rep       Date:  2010-01-29       Impact factor: 2.316

2.  Effect of alcohol on drug efflux protein and drug metabolic enzymes in U937 macrophages.

Authors:  Mengyao Jin; Priyanka Arya; Kalpeshkumar Patel; Bhupendra Singh; Peter S Silverstein; Hari K Bhat; Anil Kumar; Santosh Kumar
Journal:  Alcohol Clin Exp Res       Date:  2010-10-06       Impact factor: 3.455

Review 3.  [Pseudoxanthoma elasticum].

Authors:  M S Ladewig; C Götting; C Szliska; P C Issa; H-M Helb; I Bedenicki; H P N Scholl; F G Holz
Journal:  Ophthalmologe       Date:  2006-06       Impact factor: 1.059

Review 4.  Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Authors:  Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 5.  Genetic variation in drug transporters in ethnic populations.

Authors:  C D Cropp; S W Yee; K M Giacomini
Journal:  Clin Pharmacol Ther       Date:  2008-06-04       Impact factor: 6.875

Review 6.  Blood-brain barrier active efflux transporters: ATP-binding cassette gene family.

Authors:  Wolfgang Löscher; Heidrun Potschka
Journal:  NeuroRx       Date:  2005-01

7.  A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503.

Authors:  Anne M Traynor; Ju-Whei Lee; Gerald K Bayer; John M Tate; Sachdev P Thomas; Miroslaw Mazurczak; David L Graham; Jill M Kolesar; Joan H Schiller
Journal:  Invest New Drugs       Date:  2009-02-24       Impact factor: 3.850

Review 8.  Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution.

Authors:  Thomas Gerloff
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-04       Impact factor: 3.000

9.  Sestamibi is a substrate for MDR1 and MDR2 P-glycoprotein genes.

Authors:  Brigid Joseph; Kuldeep K Bhargava; Harmeet Malhi; Michael L Schilsky; Diwakar Jain; Christopher J Palestro; Sanjeev Gupta
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-01-21       Impact factor: 9.236

Review 10.  Management of the patient with medically refractory epilepsy.

Authors:  Tiziana Granata; Nicola Marchi; Erin Carlton; Chaitali Ghosh; Jorge Gonzalez-Martinez; Andreas V Alexopoulos; Damir Janigro
Journal:  Expert Rev Neurother       Date:  2009-12       Impact factor: 4.618

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.